Journal
ALZHEIMERS & DEMENTIA
Volume 14, Issue 7, Pages 913-924Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2018.02.009
Keywords
APOE; Prevalence; Amyloid; PET; CSF; Alzheimer's disease; Mild cognitive impairment; Subjective cognitive decline; Age; Sex; Education; Geographical location
Categories
Funding
- AXA Research Fund
- Fondation Universite Pierre et Marie Curie
- Fondation pour la Recherche sur Alzheimer, Paris, France
- program Investissements d'avenir [ANR-10-IAIHU-06]
- National Institutes of Health [P50 AG005133, RF1 AG025516, PO1 AG025204]
- Marie Curie FP7 International Outgoing Fellowship [628812]
- Instituto de Salud Carlos III (Fondo de InvestigaciOn Sanitario) [PI08/0139, PI12/02288, PI16/01652]
- NIH/NIA [RF1 AG057570, AG035137, AG032554, AG022374, AG13616, AG12101, AG08051, NIH-HLB HL111724]
- Instituto de Salud Carlos III (CIBERNED program)
- NATIONAL INSTITUTE ON AGING [R01AG012101] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Introduction: Apolipoprotein E (APOE) epsilon 4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid beta(A beta) pathology. Methods: We included 3451 A beta+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE epsilon 4 prevalence in relation to age, sex, education, and geographical location. Results: The APOE epsilon 4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in A beta+ cognitively normal and A beta+ mild cognitive impairment (P <.05) but not in A beta+ AD dementia (P =.66). The prevalence was highest in Northern Europe but did not vary by sex or education. Discussion: The APOE E4 prevalence in AD was higher than that in previous studies, which did not require presence of A beta pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location. (C) 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available